Results 81 to 90 of about 4,921,202 (211)
Langerhans cell histiocytosis; an institutional study [PDF]
Background: Langerhans cell histiocytosis is a complex rare disease of the dendritic cell system.The disease can occur at any age, with a peak at 5-10 years.
Shovana Karki, Aasia Rajbhandari
core +1 more source
Background: Pulmonary Langerhans' cell histiocytosis (histiocytosis X) is an uncommon, diffuse interstitial lung disease of unknown cause, mostly presenting in young smokers.
Mirzaie, Masoud +3 more
core +1 more source
Background Langerhans cell histiocytosis is a rare disease of the reticuloendothelial system. This report presents a novel case of Langerhans cell histiocytosis with systemic involvement that started with a simple chief complaint.
Hassan Mirmohammad Sadeghi +6 more
doaj +1 more source
Langerhans Cell Histiocytosis (LCH) and Diabetes Insipidus with Mandibular lesion
Langerhans cell histicytosis (LCH) is a rare disorder that primarily affects children. Its occurrence in adult is very rare. We report a case of 42 year old female patient who presented polyuria and polydipsia, loosing teeth and diplopia added to symptom
Sayeh Alizad jahani +3 more
core
Introduction A case of Langerhans cell histiocytosis (LGH) involving extensive area of base of skull resulting in panhypopituitarism and diabetes insipidus (DI) is reported.
Anirban Ghosh +2 more
doaj +3 more sources
Doença de células de langerhans e mama.
Langerhans cell histiocytosis (LCH) is a rare systemic disorder, with a diversified presentation and natural history. It can compromise any organ. We report a case of a 32-year-old woman who came to our clinic with an asymptomatic palpable breast mass ...
Cátia Rodrigues +4 more
doaj +1 more source
MEK inhibition achieves robust and durable responses in Erdheim–Chester disease
Abstract Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete.
Francesco Pegoraro +34 more
wiley +1 more source
Langerhans cell and non Langerhans cell histiocytosis: So different?
The Author reports the clinical and laboratory criteria that do not support the strict distinction between Langerhans cell and non Langerhans cell histiocytosis as reported in the relevant ...
C. Gelmetti
core +2 more sources
A large multilobulated cutaneous nodule in infancy
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Wahida +2 more
wiley +1 more source
ABSTRACT Erdheim–Chester disease (ECD) is a rare histiocytic disorder with heterogeneous clinical manifestations. Central nervous system (CNS) involvement is associated with poor prognosis. Although targeted therapies have improved outcomes in patients with mitogen‐activated protein kinase (MAPK) pathway alterations, optimal treatment strategies for ...
Naoki Watanabe +8 more
wiley +1 more source

